Viral Hemorrhagic Fevers

BIODEFENSE: Research Methodology and Animal Models

Volumn , Issue , 2005, Pages 227-257

  Warfield, Kelly L ^a   Jaax, Nancy K ^b   Deal, Emily M ^a   Swenson, Dana L ^a   Larsen, Tom ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85152342350     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420038118-17     Document Type: Chapter

References (255)

1. Borio, L., et al., Hemorrhagic fever viruses as biological weapons: medical and public health management, JAMA, 287 (18), 2391-405, 2002.
2. LeDuc, J. W., Epidemiology of hemorrhagic fever viruses, Rev Infect Dis 11 (Suppl 4), S730-5, 1989.
3. Biosafety in Microbiological and Biomedical Laboratories, 4 ed. U.S. Dept. of Health and Human Services Centers for Disease Control and Prevention, National Institutes of Health, Washington, D.C. 1999.
4. Williams, P. and Wallace, D., Unit 731, Japan’s Secret Biological Warfare in World War II. Free Press, New York, 1989, pp. 38-40.
5. Alibek, K. and Handelman, S., Biohazard. Random House, New York, 1999.
6. Miller, J., Engelberg, S., and Broad, W. J., Germs: Biological Weapons and America’s Secret War. Simon and Schuster, Waterville, ME, 2001.
7. Center for Nonproliferation Studies, Chemical and biological weapons: possession and programs past and present. http://cns.miis.edu/research/cbw/possess.htm, 2000.
8. Feldmann, H. and Klenk, H. D., Marburg and Ebola viruses, Adv Virus Res 47, 1-52, 1996.
9. Geisbert, T. W., Marty, A. M., and Jahrling, P. B., Viral hemorrhagic fevers, in Physician’s Guide to Terrorist Attack, Roy, M. J. Humana Press, Totowa, N.J., 2003.
10. Feldmann, H., Klenk, H. D., and Sanchez, A., Molecular biology and evolution of filoviruses, Arch Virol Suppl 7, 81-100, 1993.
11. Peters, C. J. and Khan, A. S., Filovirus diseases, Curr Top Microbiol Immunol 235, 85-95, 1999.
12. Update: filovirus infection associated with contact with nonhuman primates or their tissues, MMWR Morb Mortal Wkly Rep 39(24), 404-5, 1990.
13. Brown, D. W., Threat to humans from virus infections of non-human primates, Rev Med Virol 7(4), 239-246, 1997.
14. Update: filovirus infections among persons with occupational exposure to nonhuman primates, MMWR Morb Mortal Wkly Rep 39 (16), 266-7; 273, 1990.
15. Mwanatambwe, M., et al., Ebola hemorrhagic fever (EHF): mechanism of transmission and pathogenicity, J Nippon Med Sch 68(5), 370-5, 2001.
16. Pinzon, J. E., et al., Trigger events: enviroclimatic coupling of Ebola hemorrhagic fever outbreaks, Am J Trop Med Hyg 71(5), 664-74, 2004.
17. Jaax, N., et al., Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory, Lancet 346 (8991-8992), 1669-71, 1995.
18. Johnson, E., et al., Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus, Int J Exp Pathol 76(4), 227-36, 1995.
19. Belanov, E. F., et al., Survival of Marburg virus infectivity on contaminated surfaces and in aerosols, Vopr Virusol 41, 32-34, 1996.
20. Frolov, V. G. a. G. M., Stability of Marburg virus to lyophilization process and subsequent storage at different temperatures., Vopr Virusol 41, 275-277, 1996.
21. Martini, G. A. a. R. S., Marburg virus disease, Springer, Berlin, 1971.
22. Smith, D. H., et al., Marburg-virus disease in Kenya, Lancet 1(8276), 816-20, 1982.
23. Geisbert, T. W. and Hensley, L. E., Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions, Expert Rev Mol Med 6(20), 1-24, 2004.
24. Zeller, H., [Lessons from the Marburg virus epidemic in Durba, Democratic Republic of the Congo (1998-2000)], Med Trop (Mars) 60 (2 Suppl), 23-6, 2000.
25. Colebunders, R., et al., Organisation of health care during an outbreak of Marburg haemorrhagic fever in the Democratic Republic of Congo, 1999, J Infect 48(4), 347-53, 2004.
26. Walsh, P. D., et al., Catastrophic ape decline in western equatorial Africa, Nature 422(6932), 611-4, 2003.
27. Whitfield, J., Ape populations decimated by hunting and Ebola virus, Nature 422 (6932), 551, 2003.
28. Wilson, J. A., et al., Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins, Virology 286(2), 384-90, 2001.
29. Sanchez, A., et al., Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus, Virus Res 29(3), 215-40, 1993.
30. Volchkov, V. E., et al., GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases, Virology 214(2), 421-30, 1995.
31. Elliott, L. H., Kiley, M. P., and McCormick, J. B., Descriptive analysis of Ebola virus proteins, Virology 147(1), 169-76, 1985.
32. Muhlberger, E., et al., Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems, J Virol 73 (3), 1999.
33. Basler, C. F., et al., The Ebola virus VP35 protein functions as a type I IFN antagonist, Proc Natl Acad Sci USA 97(22), 12289-94, 2000.
34. Basler, C. F., et al., The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3, J Virol 77(14), 7945-56, 2003.
35. Ruigrok, R. W., et al., Structural characterization and membrane binding properties of the matrix protein VP40 of Ebola virus, J Mol Biol 300(1), 103-12, 2000.
36. Dessen, A., et al., Crystal structure of the matrix protein VP40 from Ebola virus, Embo J 19(16), 4228-36, 2000.
37. Swenson, D. L., et al., Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein, FEMS Immunol Med Microbiol 40(1), 27-31, 2004.
38. Kolesnikova, L., et al., The matrix protein of Marburg virus is transported to the plasma membrane along cellular membranes: exploiting the retrograde late endosomal pathway, J Virol 78(5), 2382-93, 2004.
39. Kolesnikova, L., Bugany, H., Klenk, H. D., and Becker, S., VP40, the matrix protein of Marburg virus, is associated with membranes of the late endosomal compartment, J Virol 76(4), 1825-38, 2002.
40. Bavari, S., et al., Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses, J Exp Med 195(5), 593-602, 2002.
41. Han, Z., et al., Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding, J Virol 77(3), 1793-800, 2003.
42. Licata, J. M., et al., Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles, J Virol 78(14), 7344-51, 2004.
43. Sanchez, A., et al., Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates, J Infect Dis 179 Suppl 1, S164-9, 1999.
44. Rollin, P. E., et al., Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States., J Infect Dis 179 Suppl 1, S108-14, 1999.
45. Maruyama, T., et al., Ebola virus, neutrophils, and antibody specificity, Science 282, 845, 1998.
46. Sui, J. and Marasco, W. A., Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor, Virology 303(1), 9-14, 2002.
47. Kindzelskii, A. L., et al., Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils, J Immunol 164(2), 953-8, 2000.
48. Henchal, E. A., et al., Current laboratory methods for biological threat agent identification, Clin Lab Med 21, 7.1-7.13, 2001.
49. Rollin, P. E. and Ksiazek, T. G., Ebola haemorrhagic fever, Trans R Soc Trop Med Hyg 92(1), 1-2, 1998.
50. Stroher, U., et al., Infection and activation of monocytes by Marburg and Ebola viruses, J Virol 75(22), 11025-33, 2001.
51. Geisbert, T. W., et al., Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event, J Infect Dis 188(11), 1618-29, 2003.
52. Mahanty, S., et al., Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses, J Immunol 170(6), 2797-801, 2003.
53. Bosio, C. M., et al., Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation, J Infect Dis 188(11), 1630-8, 2003.
54. Geisbert, T. W., et al., Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection, Am J Pathol 163(6), 2347-70, 2003.
55. Gupta, M., et al., Monocyte derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1 alpha and TNF-alpha and inhibit Poly-IC induced IFN-alpha in vitro, Virology 284(20), 20-25, 2001.
56. Schnittler, H. J. and Feldmann, H., Viral hemorrhagic fever - a vascular disease? Thromb Haemost 89(6), 967-72, 2003.
57. Geisbert, T. W., et al., Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells, Am J Pathol 163(6), 2371-82, 2003.
58. Chan, S. Y., et al., Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses, Cell 106(1), 117-26, 2001.
59. Simmons, G., et al., Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection, J Virol 77(24), 13433-8, 2003.
60. Becker, S., Spiess, M., and Klenk, H. D., The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus, J Gen Virol 76 (Pt 2), 393-9, 1995.
61. Alvarez, C. P., et al., C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans, J Virol 76(13), 6841-4, 2002.
62. Simmons, G., et al., DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells, Virology 305(1), 115-23, 2003.
63. Lasala, F., et al., Mannosyl glycodendritic structure inhibits DC-SIGN-mediated Ebola virus infection in cis and in trans, Antimicrob Agents Chemother 47(12), 3970-2, 2003.
64. Gupta, M., et al., Persistent infection with ebola virus under conditions of partial immunity, J Virol 78(2), 958-67, 2004.
65. Gibb, T. R., et al., Viral replication and host gene expression in alveolar macrophages infected with Ebola virus (Zaire strain), Clin Diagn Lab Immunol 9(1), 19-27, 2002.
66. Leroy, E. M., et al., Early immune responses accompanying human asymptomatic Ebola infections, Clin Exp Immunol 124(3), 453-60, 2001.
67. Leroy, E. M., et al., Human asymptomatic Ebola infection and strong inflammatory response, Lancet 355(9222), 2210-5, 2000.
68. Baize, S., et al., Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients, Nat Med 5(4), 423-6, 1999.
69. Baize, S., et al., Inflammatory responses in Ebola virus-infected patients, Clin Exp Immunol 128(1), 163-8, 2002.
70. Ksiazek, T. G., et al., Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995, 177-187, J Infect Dis 179 (Suppl 1), 1999.
71. Fisher-Hoch, et al., Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola), J Infect Dis 152(5), 887-94, 1985.
72. Connolly, B. M., et al., Pathogenesis of experimental Ebola virus infection in guinea pigs, J Infect Dis 179 (Suppl 1), S203-17, 1999.
73. Volchkov, V. E., et al., Molecular characterization of guinea pig-adapted variants of Ebola virus, Virology 277(1), 147-55, 2000.
74. Ryabchikova, E., et al., Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis, Arch Virol 141(5), 909-21, 1996.
75. Ryabchikova, E., et al., Ebola virus infection in the guinea pig, in Ebola and Marburg Viruses: Molecular and Cellular Biology, Klenk, H. and Feldmann, H., Eds., Horizon Biosciences, Norfolk, VA, 2004, pp. 239-253.
76. Hevey, M., et al., Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates, Virology 251 (1), 28-37., 1998.
77. Robin, Y., Bres, P., and Camain, R., Passage of Marburg virus in guinea pigs, in Marburg Virus, Martini, G. A. and Siegert, R., Eds., Springer, New York, 1971, pp. 117-122.
78. Ryabchikova, E., et al., Respiratory Marburg virus infection in guinea pigs, Arch Virol 141(11), 2177-90, 1996.
79. Lub, M. Y., et al., Clinical and virological characterization of the disease in guinea pigs aerogenically infected with Marburg virus, Vopr Virusol 3, 119-121, 1995.
80. Ignat’ev, G. M., et al., [The immunological indices of guinea pigs modelling Marburg hemorrhagic fever], Vopr Virusol 39(4), 169-71, 1994.
81. Jaax, N. K., et al., Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure, Arch Pathol Lab Med 120(2), 140-55, 1996.
82. Geisbert, T. W., et al., Evaluation in nonhuman primates of vaccines against Ebola virus, Emerg Infect Dis 8(5), 503-7, 2002.
83. Geisbert, T., et al., Filovirus pathogenesis in nonhuman primates, in Ebola and Marburg Viruses Molecular and Cellular Biology, Klenk, H. and Feldmann, H., Eds., Horizon Bioscience, Norfolk, VA, 2004, pp. 203-238.
84. Schou, S. and Hansen, A. K., Marburg and Ebola virus infections in laboratory nonhuman primates: a literature review, Comp Med 50 (2), 108-23., 2000.
85. Bowen, E. T., Ebola haemorrhagic fever: experimental infection of monkeys, Trans R Soc Trop Med Hyg 72(2), 188-91, 1978.
86. Bowen, E. T., et al., Virological studies on a case of Ebola virus infection in man and in monkeys, in Ebola virus haemorrhagic fever, Pattyn, S. R., Ed., Elsevier/North-Holland Biomedical, Amsterdam, The Netherlands, 1978, pp. 95-100.
87. Bowen, E. T., et al., Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent, Lancet 1(8011), 571-3, 1977.
88. Bowen, E. T. W., et al., Viral haemorrhagic fever in southern Sudan and northern Zaire, The Lancet 1(8011), 571-3, 1977.
89. Davis, K. J., et al., Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells, Arch Pathol Lab Med 121(8), 805-19, 1997.
90. Ryabchikova, E. I., Current concepts of filovirus pathogenesis, Symposium on Marburg and Ebola Viruses Marburg, Germany, October 14, 2000.
91. Ryabchikova, E. I., Kolesnikova, L. V., and Netesov, S. V., Animal pathology of filoviral infections, Curr Top Microbiol Immunol 235, 145-73, 1999.
92. Reed, D. S., et al., Depletion of peripheral blood T lymphocytes and NK cells during the course of Ebola hemorrhagic fever in cynomolgus macaques, Viral Immunol 17(3), 390-400, 2004.
93. Simpson, D. I., Zlotnik, I., and Rutter, D. A., Vervet monkey disease: Experimental infection of guinea pigs and monkeys with the causative agents, Br J Exp Pathol 49, 458-64, 1968.
94. Simpson, D. I., Marburg agent disease, Trans R Soc Trop Med Hyg 63, 303-9, 1969.
95. Haas, R. and Maass, G., Experimental infection of monkeys with the Marburg virus, in Marburg Virus, Martini, G. A. and Siegert, R., Eds., Springer, New York, 1971, pp. 136-143.
96. Zlotnik, I., Marburg Agent disease: pathology, Trans R Soc Trop Med Hyg 63, 310-23, 1969.
97. Oehlert, W., The morphologic picture in livers, spleens, and lymph nodes of monkeys and guinea pigs after infections with the “Vervet Agent”, in Marburg Virus, Martini, G. A. and Siegert, R., Eds., Springer, New York, 1971, pp. 144-156.
98. Murphy, F. A., et al., Marburg virus infection in monkeys. Ultrastructural studies, Lab Invest 24(4), 279-91, 1971.
99. Geisbert, T. W. and Jaax, N. K., Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy, Ultrastruct Pathol 22(1), 3-17, 1998.
100. Geisbert, T. W., et al., Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses, Lab Invest 80(2), 171-86, 2000.
101. Fisher-Hoch, S. P., et al., Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management, Lancet 2(8358), 1055-8, 1983.
102. Hart, M. K., Vaccine research efforts for filoviruses, Int J Parasitol 33, 583-95, 2003.
103. Jahrling, P. B., et al., Preliminary report: isolation of Ebola virus from monkeys imported to USA, Lancet 335(8688), 502-5, 1990.
104. Jahrling, P. B., et al., Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic, Arch Virol Suppl 11, 115-34, 1996.
105. Ignatiev, G. M., et al., Immune and pathophysiological processes in baboons experimentally infected with Ebola virus adapted to guinea pigs, Immunol Lett 71(2), 131-40, 2000.
106. Luchko, S. V., et al., [Experimental study of Ebola hemorrhagic fever in baboon models], Biull Eksp Biol Med 120(9), 302-4, 1995.
107. Mikhailov, V. V., et al., [The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever], Vopr Virusol 39(2), 82-4, 1994.
108. Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z. Y., and Nabel, G. J., Development of a preventive vaccine for Ebola virus infection in primates, Nature 408(6812), 605-9, 2000.
109. Bray, M., Pathogenesis of filovirus infection in mice, in Ebola and Marburg Viruses, Klenk, H. and Feldmann, H., Eds., Horizon Biosciences, Norfolk, VA, 2004, pp. 255-77.
110. Bray, M., et al., A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever, J Infect Dis 178(3), 651-61, 1998.
111. Bray, M., et al., Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus, J Comp Pathol 125(4), 255-277, 2001.
112. Bray, M. and Huggins, J., Studies of the pathogenesis of filovirus infection using a mouse-adapted variant of Ebola Zaire virus, in Symposium on Marburg and Ebola Viruses, Marburg, Germany, October 1-4, 2000, pp. 23.
113. Bray, M., et al., A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever, J Infect Dis 179 Suppl 1, S248-58, 1999.
114. Gupta, M., et al., Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication, J Virol 75(10), 4649-54, 2001.
115. Mahanty, S., et al., Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection, Virology 312(2), 415-24, 2003.
116. Gibb, T. R., et al., Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice, J Comp Pathol 125(4), 233-42, 2001.
117. Warfield, K. L., et al., Ebola virus-like particles protect from lethal Ebola virus infection, Proc Natl Acad Sci USA 100(26), 15889-94, 2003.
118. Warfield, K. L., et al., Role of natural killer cells in innate protection against lethal Ebola virus infection, J Exp Med 200(2), 169-79, 2004.
119. Huggins, J., Zhang, Z. X., and Bray, M., Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model, J Infect Dis 179 (Suppl 1), S240-7, 1999.
120. Pushko, P., et al., Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus, Vaccine 19(1), 142-53, 2000.
121. Vanderzanden, L., et al., DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge, Virology 246(1), 134-44, 1998.
122. Rao, M., et al., Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A, Vaccine 17 (23-24), 2991-8, 1999.
123. Rao, M., et al., Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells, J Virol 76(18), 9176-85, 2002.
124. Warfield, K. L., et al., Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection, J Immunol 175(2), 1184-91, 2005.
125. Bray, M., Driscoll, J., and Huggins, J. W., Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor, Antiviral Res 45(2), 135-47, 2000.
126. SoRelle, R., Antibodies that protect mice against ebola virus hold promise of vaccine and therapy for disease, Circulation 101 (10), E9020, 2000.
127. Bray, M., et al., 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice, Antiviral Res 55(1), 151-9, 2002.
128. Zlotnik, I. and Simpson, D. I., The Pathology of Experimental Vervet Monkey Disease in Hamsters, Br J Exp Pathol 50, 393-9, 1969.
129. Ignatev, G. M., et al., A comparative study of the immunological indices in guinea pigs administered an inactivated Marburg virus, Vopr Virusol 36, 421-3, 1991.
130. Hevey, M., et al., Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants, Virology 239(1), 206-16, 1997.
131. Riabchikova, E. I., et al., [The morphological changes in Ebola infection in guinea pigs], Vopr Virusol 38(4), 176-9, 1993.
132. Ryabchikova, E. I., Kolesnikova, L. V., and Luchko, S. V., An analysis of features of pathogenesis in two animal models of Ebola virus infection, J Infect Dis 179 (Suppl 1), S199-202, 1999.
133. Solcher, H., Neuropathological findings in experimentally infected guinea pigs, in Marburg Virus, Martini, G. A. and Siegert, R., Eds., Springer, New York, 1971, pp. 125-128.
134. Tikunova, N. V., Kolokol’tsov, A. A., and Chepurnov, A. A., Recombinant monoclonal human antibodies against Ebola virus, Dokl Biochem Biophys 378, 195-7, 2001.
135. Maruyama, T., et al., Recombinant human monoclonal antibodies to Ebola virus, J Infect Dis 179 (Suppl 1), S235-9, 1999.
136. Jahrling, P. B., et al., Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses, Arch Virol Suppl 11, 135-40, 1996.
137. Jahrling, P. B., et al., Evaluation of immune globulin and recombinant interferonalpha2b for treatment of experimental Ebola virus infections, J Infect Dis 179 (Suppl 1), S224-34, 1999.
138. Parren, P. W., et al., Pre-and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody, J Virol 76(12), 6408-12, 2002.
139. Wilson, J. A., et al., Epitopes involved in antibody-mediated protection from Ebola virus, Science 287(5458), 1664-6, 2000.
140. Oldstone, M. B., Arenaviruses I: the epidemiology, molecular and cell biology of arenaviruses, in Current Topics in Microbiology and Immunology, Springer, New York, 2002.
141. Downs, W., et al., Tacaribe virus, a new agent isolated from Artibeus bats and mosquitos in Trinidad, West Indies, Am J Trop Med Hyg 12, 640-6, 1963.
142. Salvato, M. S., Molecular biology of the prototype arenavirus, lymphocytic choriomeningitis virus, in The Arenaviridae, Salvato, M. S. Plenum, New York, 1993, pp. 133-56.
143. Johnson, K. M., et al., Isolation of Machupo virus from wild rodent Calomys callosus, Am J Trop Med Hyg 15(1), 103-6, 1966.
144. Carey, D. E., et al., Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria, Trans R Soc Trop Med Hyg 66(3), 402-8, 1972.
145. White, H. A., Lassa fever. A study of 23 hospital cases, Trans R Soc Trop Med Hyg 66(3), 390-401, 1972.
146. Monath, T. P., et al., A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972, Am J Trop Med Hyg 22(6), 773-9, 1973.
147. Peters, C. J., et al., Hemorrhagic fever in Cochabamba, Bolivia, 1971, Am J Epidemiol 99(6), 425-33, 1974.
148. Johnson, K. M., Arenaviruses, epidemiology and control, in Viral Infections of Humans, 3rd ed. Plenum, New York, 1989, pp. 133-47.
149. Peters, C. J., et al., Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever contrasted, Rev Infect Dis 11 (Suppl 4), S743-9, 1989.
150. Jahrling, P. B., et al., Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin, J Infect Dis 141(5), 580-9, 1980.
151. McCormick, J. B., et al., A prospective study of the epidemiology and ecology of Lassa fever, J Infect Dis 155(3), 437-44, 1987.
152. Johnson, K. M., et al., Clinical virology of Lassa fever in hospitalized patients, J Infect Dis 155(3), 456-64, 1987.
153. McCormick, J. B., et al., A case-control study of the clinical diagnosis and course of Lassa fever, J Infect Dis 155(3), 445-55, 1987.
154. McCormick, J. B., Epidemiology and control of Lassa fever, Curr Top Microbiol Immunol 134, 69-78, 1987.
155. Fisher-Hoch, S., Pathophysiology of shock and haemorrhage in viral haemorrhagic fevers, Southeast Asian J Trop Med Public Health 18(3), 390-1, 1987.
156. Schmitz, H., et al., Monitoring of clinical and laboratory data in two cases of imported Lassa fever, Microbes Infect 4(1), 43-50, 2002.
157. McCormick, J. B. and Fisher-Hoch, S. P., Lassa fever, Curr Top Microbiol Immunol 262, 75-109, 2002.
158. Stephen, E. L. and Jahrling, P. B., Experimental Lassa fever virus infection successfully treated with ribavirin, Lancet 1(8110), 268-9, 1979.
159. Kiley, M. P., Lange, J. V., and Johnson, K. M., Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus, Lancet 2 (8145), 738, 1979.
160. Callis, R. T., Jahrling, P. B., and DePaoli, A., Pathology of Lassa virus infection in the rhesus monkey, Am J Trop Med Hyg 31(5), 1038-45, 1982.
161. Jahrling, P. B. and Peters, C. J., Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain, Infect Immun 44(2), 528-33, 1984.
162. Jahrling, P. B., Peters, C. J., and Stephen, E. L., Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys, J Infect Dis 149(3), 420-7, 1984.
163. Evseev, A. A., et al., [Experimental Lassa fever in hamadryas baboons], Vopr Virusol 36(2), 150-2, 1991.
164. Stephenson, E. H., Larson, E. W., and Dominik, J. W., Effect of environmental factors on aerosol-induced Lassa virus infection, J Med Virol 14(4), 295-303, 1984.
165. Walker, D. H., et al., Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus, J Infect Dis 146(3), 360-8, 1982.
166. Fisher-Hoch, S. P. and McCormick, J. B., Pathophysiology and treatment of Lassa fever, Curr Top Microbiol Immunol 134, 231-9, 1987.
167. Fisher-Hoch, S. P., et al., Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever, J Infect Dis 155(3), 465-74, 1987.
168. Ignat’ev, G. M., et al., [Study of certain indicators of immunity upon infecting CBA/Calac line mice with Lassa virus], Vopr Virusol 39(6), 257-60, 1994.
169. Ignat’ev, G. M., [Immunogenic and protective characteristics of recombinant Lassa virus NP protein], Vopr Virusol 47(2), 28-31, 2002.
170. Uckun, F. M., et al., Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus, BMC Infect Dis 4 (1), 1, 2004.
171. Barkar, N. D. and Lukashevich, I. S., [Lassa and Mozambique viruses: cross protection in experiments on mice and action of immunosuppressants on experimental infections], Vopr Virusol 34(5), 598-603, 1989.
172. Barkar, N. D., et al., [Effect of immunosuppression on the development and outcome of an acute infection in mice caused by administration of the Lassa virus], Vopr Virusol 34(2), 208-13, 1989.
173. Lukashevich, I. S., et al., [Pathogenicity of the Lassa virus for laboratory mice], Vopr Virusol 30(5), 595-9, 1985.
174. Jahrling, P. B., et al., Pathogenesis of Lassa virus infection in guinea pigs, Infect Immun 37(2), 771-8, 1982.
175. Walker, D. H., et al., Comparative pathology of Lassa virus infection in monkeys, guinea pigs, and Mastomys natalensis, Bull World Health Organ 52, 535-45, 1975.
176. Jahrling, P. B., Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin, J Med Virol 12(2), 93-102, 1983.
177. Zhang, L., et al., Reassortant analysis of guinea pig virulence of pichinde virus variants, Virology 290(1), 30-8, 2001.
178. Huggins, J. W., Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug, Rev Infect Dis 11 (Suppl 4), S750-61, 1989.
179. Pushko, P., et al., Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses, J Virol 75(23), 11677-85, 2001.
180. Oldstone, M. B., et al., Virus and immune responses: lymphocytic choriomeningitis virus as a prototype model of viral pathogenesis, Br Med Bull 41(1), 70-4, 1985.
181. Oldstone, M. B., Biology and pathogenesis of lymphocytic choriomeningitis virus infection, Curr Top Microbiol Immunol 263, 83-117, 2002.
182. Ciurea, A., et al., Viral escape from the neutralizing antibody response: the lymphocytic choriomeningitis virus model, Immunogenetics 53(3), 185-9, 2001.
183. Wilson, M. L., et al., Rift Valley fever in rural northern Senegal: human risk factors and potential vectors, Am J Trop Med Hyg 50(6), 663-75, 1994.
184. Shope, R. E., Peters, C. J., and Davies, F. G., The spread of Rift Valley fever and approaches to its control, Bull World Health Organ 60(3), 299-304, 1982.
185. Jouan, A., et al., Analytical study of a Rift Valley fever epidemic, Res Virol 140(2), 175-86, 1989.
186. Daubney, R., Hudson, J., and Garnham, P., Enzootic hepatitis or Rift Valley fever: an undescribed virus disease of sheep, cattle, and man from East Africa, J Path Bact 34, 545-579, 1931.
187. Findley, G. M., Rift Valley Fever or enzootic hepatitis, Trans R Soc Trop Med Hyg 25, 229, 1932.
188. Turell, M. J. and Kay, B. H., Susceptibility of selected strains of Australian mosquitoes (Diptera: Culicidae) to Rift Valley fever virus, J Med Entomol 35(2), 132-5, 1998.
189. Gargan, T. P., 2nd, et al., Vector potential of selected North American mosquito species for Rift Valley fever virus, Am J Trop Med Hyg 38(2), 440-6, 1988.
190. Gear, J. H. S., Rift valley fever, in CRC Handbook of Viral and Rickettsial Hemorrhagic Fevers, Gear, J. H. S., Ed., CRC Press, Boca Raton, FL, 2000.
191. CDC, Management of patients with suspected viral hemorrhagic fever, MMWR Morb Mortal Wkly Rep 37 (Suppl S3), 1-16, 1988.
192. El-Karamany, R., Imam, I., and Farid, A., Production of inactivated RVF vaccine, J Egypt Publ Health Assoc 56, 495-525, 1981.
193. Niklasson, B., et al., Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans, Vaccine 3(2), 123-7, 1985.
194. Pittman, P. R., et al., Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience, Vaccine 18 (1-2), 181-9, 1999.
195. Morrill, J. C. and Peters, C. J., Pathogenicity and neurovirulence of a mutagenattenuated Rift Valley fever vaccine in rhesus monkeys, Vaccine 21 (21-22), 2994-3002, 2003.
196. Harrington, D. G., et al., Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep, Am J Vet Res 41(10), 1559-64, 1980.
197. Peters, C. J. and Slone, T. W., Inbred rat strains mimic the disparate human response to Rift Valley fever virus infection, J Med Virol 10(1), 45-54, 1982.
198. McIntosh, B. M., Dickinson, D. B., and dos Santos, I., Rift Valley fever. 3. Viraemia in cattle and sheep. 4. The susceptibility of mice and hamsters in relation to transmission of virus by mosquitoes, J S Afr Vet Assoc 44(2), 167-9, 1973.
199. Morrill, J. C., et al., Prevention of Rift Valley fever in rhesus monkeys with interferonalpha, Rev Infect Dis 11 Suppl 4, S815-25, 1989.
200. Morrill, J. C., et al., Rift Valley fever infection of rhesus monkeys: implications for rapid diagnosis of human disease, Res Virol 140(2), 139-46, 1989.
201. Morrill, J. C., et al., Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response, Arch Virol 110 (3-4), 195-212, 1990.
202. Morrill, J. C., Czarniecki, C. W., and Peters, C. J., Recombinant human interferongamma modulates Rift Valley fever virus infection in the rhesus monkey, J Interferon Res 11(5), 297-304, 1991.
203. Peters, C. J., et al., Experimental Rift Valley fever in rhesus macaques, Arch Virol 99 (1-2), 31-44, 1988.
204. Niklasson, B. S., Meadors, G. F., and Peters, C. J., Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters, Acta Pathol Microbiol Immunol Scand [C] 92(4), 197-200, 1984.
205. Anderson, G. W., Jr., Slone, T. W., Jr., and Peters, C. J., The gerbil, Meriones unguiculatus, a model for Rift Valley fever viral encephalitis, Arch Virol 102 (3-4), 187-96, 1988.
206. Johnson, B. K., et al., Marburg, Ebola and Rift Valley Fever virus antibodies in East African primates, Trans R Soc Trop Med Hyg 76(3), 307-10, 1982.
207. Mason, P. J. and Mims, C. A., Rift Valley fever virus in mice. V. The properties of a haemagglutinin present in infective serum, Br J Exp Pathol 37(5), 423-33, 1956.
208. Mims, C. A., The coagulation defect in Rift Valley fever and yellow fever virus infections, Ann Trop Med Parasitol 50(2), 147-9, 1956.
209. Mims, C. A., Rift Valley Fever virus in mice. IV. Incomplete virus; its production and properties, Br J Exp Pathol 37(2), 129-43, 1956.
210. Mims, C. A., Rift Valley Fever virus in mice. III. Further quantitative features of the infective process, Br J Exp Pathol 37(2), 120-8, 1956.
211. Mims, C. A., Rift Valley Fever virus in mice. II. Adsorption and multiplication of virus, Br J Exp Pathol 37(2), 110-9, 1956.
212. Mims, C. A., Rift Valley Fever virus in mice. I. General features of the infection, Br J Exp Pathol 37(2), 99-109, 1956.
213. Peters, C. J., et al., Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator, Antiviral Res 6(5), 285-97, 1986.
214. Kende, M., et al., Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice, Antimicrob Agents Chemother 31(7), 986-90, 1987.
215. Kende, M., et al., Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death, Antimicrob Agents Chemother 31(8), 1194-8, 1987.
216. Bennett, D. G., Jr., Glock, R. D., and Gerone, P. J., Protection of mice and lambs against pantropic Rift Valley Fever Virus, using immune serum, Am J Vet Res 26, 57-61, 1965.
217. Higashihara, M., Heat-and acid-labile virus-inhibiting factor or interferon induced by Rift Valley fever virus in mice, Jpn J Microbiol 15(5), 482-4, 1971.
218. Kasahara, S. and Koyama, H., Long term existence of Rift Valley Fever virus in immune mice, Kitasato Arch Exp Med 46 (3-4), 105-12, 1973.
219. Tomori, O. and Kasali, O., Pathogenicity of different strains of Rift Valley fever virus in Swiss albino mice, Br J Exp Pathol 60(4), 417-22, 1979.
220. Canonico, P. G., et al., Inhibition of RNA viruses in vitro and in Rift Valley fever-infected mice by didemnins A and B, Antimicrob Agents Chemother 22(4), 696-7, 1982.
221. Anderson, A. O., et al., Mucosal priming alters pathogenesis of Rift Valley fever, Adv Exp Med Biol 237, 717-23, 1988.
222. Vialat, P., et al., The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice, J Virol 74(3), 1538-43, 2000.
223. Anderson, G. W., Jr., Slone, T. W., Jr., and Peters, C. J., Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats, Microb Pathog 2(4), 283-93, 1987.
224. Anderson, G. W., Jr. and Peters, C. J., Viral determinants of virulence for Rift Valley fever (RVF) in rats, Microb Pathog 5(4), 241-50, 1988.
225. Anderson, G. W., Jr., et al., Infection of inbred rat strains with Rift Valley fever virus: development of a congenic resistant strain and observations on age-dependence of resistance, Am J Trop Med Hyg 44(5), 475-80, 1991.
226. Ritter, M., et al., Resistance to Rift Valley fever virus in Rattus norvegicus: genetic variability within certain “inbred” strains, J Gen Virol 81 (Pt 11), 2683-8, 2000.
227. Anderson, G. W., Jr., et al., Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats, Vaccine 9(10), 710-4, 1991.
228. Rosebrock, J. A., Schellekens, H., and Peters, C. J., The effects of ageing in vitro and interferon on the resistance of rat macrophages to Rift Valley Fever virus, Anatomical Record 205, A165-A166., 1983.
229. Rosebrock, J. A. and Peters, C. J., Cellular resistance to Rift Valley fever virus (RVFV) infection in cultured macrophages and fibroblasts from genetically resistant and susceptible rats, In Vitro 18, 308, 1982.
230. World Health Organization, Prevention and control of dengue and dengue haemorrhagic fever: comprehensive guidelines, WHO regional publication, SEARO, 1999.
231. Pinheiro, F. and Corber, S. J., Global situation of dengue and dengue hemorrhagic fever and its emergence in the Americas, World Health Stat Q 50, 161-8, 1997.
232. Ho, L. J., et al., Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production, J Immunol 166, 1499-506, 2001.
233. Malavige, G. N., et al., Dengue viral infections, Postgrad Med 80, 588-601, 2004.
234. Kroeger, A., Nathan, M., and Hombach, J., Dengue, Nature Rev Microbiol 2, 360-1, 2004.
235. Henchal, E. A., et al., Rapid identification of dengue virus isolates by using monoclonal antibodies in an indirect immunofluorescence assay, Am J Trop Med Hyg 32, 164-9, 1983.
236. Guzman, M. G. and Kouri, G., Dengue: an update, Lancet Infect Dis 2, 33-42, 2002.
237. Rottman, A. L., Dengue: defining protective versus pathologic immunity, J Clin Invest 113(7), 946-51, 2004.
238. Halstead, S. B., Pathogenesis of dengue: challenges to molecular biology, Science 239, 476-81, 1988.
239. Littaua, R., Kurane, I., and Ennis, F. A., Human IgG Fc receptor II mediates antibodydependent enhancement of dengue virus infection, J Immunol 144, 3183-6, 1990.
240. Perikov, Y., Development of dengue vaccines, Dengue Bulletin 24, 71-6, 2000.
241. Meiklejohn, G., England, B., and Lennette, E. H., Adaptation of dengue virus strains in unweaned mice, Am J Trop Med Hyg 1, 51-8, 1952.
242. Johnson, A. J. and Roehrig, J. T., New mouse model for dengue virus vaccine testing, J Virol 73, 783-6, 1999.
243. An, J., Kimura-Kuroda, J., Hirabayashi, Y., and Yasui, K., Development of a novel mouse model for dengue virus infection, Virology 263, 70-7, 1999.
244. Lin, H. S., et al., Study of dengue virus infection in SCID mice engrafted with human K562 cells, J Virol 72, 9729-37, 1998.
245. Wu, S. J., et al., Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection, Am J Trop Med Hyg 52(5), 468-76, 1995.
246. Huang, K.-J., et al., Manifestation of thrombocytopenia in dengue-2-virus-infected mice, J Gen Virol 81, 2177-82, 2000.
247. Halstead, S. B., Shotwell, H., and Casals, J., Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection, J Infect Dis 128(1), 7-14, 1973.
248. Halstead, S. B., Shotwell, H., and Casals, J., Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection, J Infect Dis 128(1), 15-22, 1973.
249. Marchette, N. J., et al., Studies on the pathogenesis of dengue infection in monkeys. III. Sequential distribution of virus in primary and heterologous infections, J Infect Dis 128(1), 23-30, 1973.
250. Scherer, W. F., et al., Experimental infection of chimpanzees with dengue viruses, Am J Trop Med Hyg 27(3), 590-9, 1978.
251. Angsubhakorn, S., et al., Neurovirulence detection of dengue virus using rhesus and cynomolgus monkeys, J Virol Methods 18(1), 13-24, 1987.
252. Malinoski, F. J., et al., Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys, Antiviral Res 13(3), 139-49, 1990.
253. Brueckner, A. L., Reagan, R. L., and Yancey, F. S., Studies of dengue fever virus (Hawaii mouse adapted) in lactating hamsters, Am J Trop Med Hyg 5(5), 809-11, 1956.
254. Tarr, G. C. and Lubiniecki, A. S., Chemically-induced temperature-sensitive mutants of dengue virus type 2. I. Isolation and partial characterization, Arch Virol 48, 279-87, 1975.
255. Tarr, G. C. and Lubiniecki, A. S., Chemically induced temperature-sensitive mutants of dengue virus type 2: comparison of temperature sensitivity in vitro with infectivity in suckling mice, hamsters, and rhesus monkeys, Infect Immun 13(3), 688-95, 1976.